|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
9850686 |
| 003 |
ICU |
| 005 |
20140128113300.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130425s2013 nyu o 001 0 eng d |
| 020 |
|
|
|a 9781461453802 (electronic bk.)
|
| 020 |
|
|
|a 1461453801 (electronic bk.)
|
| 020 |
|
|
|z 9781461453796
|
| 035 |
|
|
|a (OCoLC)840799397
|
| 040 |
|
|
|a GW5XE
|c GW5XE
|d YDXCP
|d COO
|d ZMC
|d OHS
|d E7B
|d OCLCA
|d IDEBK
|d I9W
|
| 049 |
|
|
|a CGUA
|
| 082 |
0 |
4 |
|a 615.3/72
|2 23
|
| 090 |
|
|
|a QR189
|b .N68 2013
|
| 096 |
|
|
|a QW 805
|
| 245 |
0 |
0 |
|a Novel immune potentiators and delivery technologies for next generation vaccines /
|c Manmohan Singh, editor.
|
| 260 |
|
|
|a New York :
|b Springer,
|c c2013.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/c
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/cr
|
| 505 |
0 |
0 |
|t Novel Immune Potentiators and delivery systems for enhancing vaccine potency --
|t TLR7/8 Agonists as Vaccine Adjuvants /
|r Mark A. Tomai, John P. Vasilakos --
|t Preclinical and Clinical Development of Synthetic iNKT-Cell Glycolipid Agonists as Vaccine Adjuvants /
|r Josianne Nitcheu, Sandrine Crabe, Gwyn Davies, Vincent Serra --
|t Mucosal Vaccination: Opportunities and Challenges /
|r Olga Borges, Gerrit Borchard --
|t Oral Vaccination: Attenuated and Gene-Based /
|r Wendy Peters, Ciaran D. Scallan, Sean N. Tucker --
|t Design and Development of next generation vaccines --
|t Development of Biophysical Assays to Better Understand Adjuvanted Vaccine Formulation Potency and Stability /
|r James Chesko, Thomas Vedvick, Steve Reed --
|t High Throughput Screening for Stabilizers of Vaccine Antigens /
|r C. Russell Middaugh, David B. Volkin, Sangeeta B. Joshi --
|t Exploring Novel Analytical Tools to Improve Characterization of Vaccine Formulations /
|r Michele Pallaoro --
|t Immunobioengineering Approaches Towards Combinatorial Delivery of Immune-Modulators and Antigens /
|r Ankur Singh, Pallab Pradhan, Krishnendu Roy --
|t Novel Delivery Technologies for vaccines --
|t Current Status of Electroporation Technologies for Vaccine Delivery /
|r Claire F. Evans, Drew Hannaman --
|t Microneedles for Intradermal Vaccination: Immunopotentiation and Formulation Aspects /
|r Alexander K. Andrianov --
|t MicroCor® Transdermal Delivery System: A Safe, Efficient, and Convenient Transdermal System for Vaccine Administration /
|r Parminder Singh, Guohua Chen, Wade Worsham --
|t Mimopath[TM]-Based Vaccine Delivery /
|r Kees Leenhouts --
|t Novel Particulate delivery systems for vaccines and adjuvants --
|t NanoBio[TM] Nanoemulsion for Mucosal Vaccine Delivery /
|r Tarek Hamouda, Jakub Simon, Ali Fattom, James Baker --
|t Influenza Virosomes as Antigen Delivery System /
|r Christian Moser, Mario Amacker --
|t Matrix M Adjuvant Technology /
|r Karin Lövgren Bengtsson --
|t Safety assessment of next generation vaccines --
|t Strategies for the Nonclinical Safety Assessment of Vaccines /
|r Jayanthi J. Wolf, Lisa M. Plitnick, Danuta J. Herzyk --
|t Safety Challenges Facing Next Generation Vaccines and the Role for Biomarkers /
|r S. Sohail Ahmed, Ernesto Oviedo-Orta, Jeffrey Ulmer.
|
| 500 |
|
|
|a Includes index.
|
| 520 |
|
|
|a Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations--many of which will be nanoparticulates--can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies.
|
| 650 |
1 |
2 |
|a Vaccines
|x immunology.
|
| 650 |
2 |
2 |
|a Adjuvants, Immunologic.
|
| 650 |
2 |
2 |
|a Drug Delivery Systems.
|
| 650 |
2 |
2 |
|a Immunotherapy.
|
| 650 |
|
0 |
|a Vaccines.
|0 http://id.loc.gov/authorities/subjects/sh85141718
|
| 650 |
|
0 |
|a Vaccines
|x Biotechnology.
|0 http://id.loc.gov/authorities/subjects/sh91002761
|
| 650 |
|
0 |
|a Immunology.
|0 http://id.loc.gov/authorities/subjects/sh85064579
|
| 653 |
|
4 |
|a Medicine.
|
| 653 |
|
4 |
|a Immunology.
|
| 653 |
|
4 |
|a Microbiology.
|
| 653 |
|
4 |
|a Vaccines.
|
| 653 |
|
4 |
|a Pharmaceutical technology.
|
| 653 |
|
4 |
|a Biomedicine.
|
| 653 |
|
4 |
|a Medical Microbiology.
|
| 655 |
|
4 |
|a Electronic books.
|
| 650 |
|
7 |
|a Immunology.
|2 fast
|0 http://id.worldcat.org/fast/fst00968006
|
| 650 |
|
7 |
|a Vaccines.
|2 fast
|0 http://id.worldcat.org/fast/fst01163573
|
| 650 |
|
7 |
|a Vaccines
|x Biotechnology.
|2 fast
|0 http://id.worldcat.org/fast/fst01163574
|
| 700 |
0 |
|
|a Manmohan Singh,
|d 1964 November 8-
|0 http://id.loc.gov/authorities/names/n2006185418
|1 http://viaf.org/viaf/44621756
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-1-4614-5380-2
|y SpringerLink
|
| 903 |
|
|
|a HeVa
|
| 035 |
|
|
|a (ICU)9850686
|
| 929 |
|
|
|a eresource
|
| 999 |
f |
f |
|i 4cdcd792-f0ef-565e-af86-8e6db3727576
|s 976bf28f-fdb4-5a8d-9460-d40b903a2e1c
|
| 928 |
|
|
|t Library of Congress classification
|a QR189 .N68 2013
|l Online
|c UC-FullText
|u http://dx.doi.org/10.1007/978-1-4614-5380-2
|z SpringerLink
|g ebooks
|i 11492519
|
